Submission of financial results for the quarter June 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals (formerly Trimurthi Limited) reported unaudited Q1 FY26 results. Revenue from operations stood at approximately Rs. 2,235 lakhs, with virtually all of it coming from the pharma (bulk drugs) segment. Profit after tax came in at Rs. 10.70 lakhs (basic EPS Rs. 0.09) versus a loss of about Rs. 35.35 lakhs in the corresponding quarter last year (Q1 FY25), when revenue was only Rs. 50.11 lakhs. Profit before tax was Rs. 16.94 lakhs. For full-year FY25, revenue was Rs. 3,071.85 lakhs and PAT was Rs. 8.45 lakhs. The auditor (CVS Balachandra Rao & Co.) issued an unmodified limited review report with no qualifications.
The company has sharply scaled up operations year-on-year — revenue has multiplied several times versus the same quarter last year, and it has swung from a loss to a small profit. However, margins remain thin and absolute profit levels are still modest, so the stock is likely to see a modest positive reaction rather than a major re-rating.